MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD

Bone Marrow Transplant. 2017 Aug;52(8):1221-1224. doi: 10.1038/bmt.2017.107. Epub 2017 Jun 5.

Authors

A-M Boekstegers¹, F Blaeschke¹, I Schmid¹, V Wiebking¹, S Immler¹, F Hoffmann¹, K Bochmann², S Müller³, T G P Grünewald⁴, J Feucht⁵, T Feuchtinger¹

Affiliations

¹ Department of Paediatric Hematology, Oncology and Stem Cell Transplantation, Dr von Hauner University Children's Hospital, Ludwig Maximilian University, Munich, Germany.
² Department of Clinical Radiology, Institute for Clinical Radiology, Ludwig Maximilian University, Munich, Germany.
³ Institute of Pathology, Ludwig Maximilian University, Munich, Germany.
⁴ Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Ludwig Maximilians University, Munich, Germany.
⁵ Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, NY, USA.

PMID: 28581460
DOI: 10.1038/bmt.2017.107

No abstract available

Publication types

Case Reports

MeSH terms

Allografts
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Child
Fatal Outcome
Female
Graft vs Host Disease* / blood
Graft vs Host Disease* / chemically induced
Graft vs Host Disease* / pathology
Humans
Neoplasm, Residual
Off-Label Use*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / blood
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Stem Cell Transplantation*

Substances

Antibodies, Monoclonal, Humanized
PDCD1 protein, human
Programmed Cell Death 1 Receptor
pembrolizumab